Australian Clinical Trials Alliance (ACTA) recommendations on improving engagement, involvement and participation of people from culturally and linguistically diverse (CALD) backgrounds in clinical trials

Australian Clinical Trials Alliance (ACTA) is the national peak body supporting and representing networks of clinician-researchers conducting investigator-initiated clinical trials, maintaining clinical quality registries, and operating clinical trial coordinating centres within the Australian healthcare system.

ACTA is undertaking a project that aims to facilitate a clinical trials system that will work cohesively to improve participation in clinical trials for people from culturally and linguistically diverse (CALD) backgrounds, with the development of recommendations underpinned by community and sector consultation. Stakeholder feedback was sought on a consultation paper into the feasibility of specific recommendations and actions to be taken to drive engagement, involvement and participation of people from CALD backgrounds in relation to all aspects of clinical trials.

ACTA asked stakeholders to outline what factors and systemic changes to the clinical trials framework would enable interested organisations support for people from CALD backgrounds to meaningfully engage with and benefit from clinical trials in a sustainable way.

Cancer Council expressed support for the proposed model outlined by ACTA, to apply a systems approach to improve CALD engagement in clinical trials. This approach would require appropriate resource investment to ensure that CALD community and representative organisations are able to support people from CALD backgrounds in clinical trials. The success of ACTA’s framework and approach would rely on how well it recognises and is responsive to the fact that people from CALD backgrounds are not a homogenous group. People from CALD backgrounds are individuals whose particular culture, language or migration pathway can brings significant additional vulnerabilities that need to be addressed before clinical trial participation is realised.

Information about the progress of the consultation, can be found on the consultation’s webpage.